Welcome to LookChem.com Sign In|Join Free
  • or
Bifonazole is a topically-active imidazole antifungal compound with broad-spectrum activity against various fungi, molds, yeasts, dimorphic fungi, and some Gram-positive bacteria. It is the first topical broad-spectrum antimycotic approved for once-daily administration and demonstrates potent inhibitory effects on cytochrome P450 aromatase, which is involved in estrogen biosynthesis. When applied topically, Bifonazole shows prolonged retention in the skin with minimal percutaneous absorption, thus minimizing its impact on aromatase.

60628-96-8

Post Buying Request

60628-96-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

60628-96-8 Hazards Identification

Pictogram(s):

Signal:

Warning

GHS Hazard Statements:

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

Precautionary Statement Codes:

P264, P270, P301+P317, P330, and P501

Hazard Classes and Categories:

Acute Tox. 4 (100%)

60628-96-8 Usage

Chemical Description

Bifonazole is an antifungal medication, while pyrazole is a heterocyclic organic compound.

Uses

Used in Antifungal Treatments:
Bifonazole is used as an imidazole antifungal agent for the treatment of various fungal infections, including dermatophytes, molds, yeasts, and dimorphic fungi. It inhibits the biosynthesis of ergosterol, an essential component of fungal cell membranes, and also acts as a calmodulin antagonist, leading to a reduction in glycolysis and ATP levels in infected cells.
Used in Antibacterial Applications:
Bifonazole is used as an antibacterial agent, effective against some Gram-positive bacteria. Its broad-spectrum activity and ability to inhibit essential cellular processes make it a valuable component in combating bacterial infections.
Used in Aromatase Inhibition:
Bifonazole is used as a potent inhibitor of cytochrome P450 aromatase, which catalyzes the biosynthesis of estrogens from androgens. Its topical application results in prolonged retention in the skin and minimal percutaneous absorption, thus reducing its systemic effects on aromatase and making it suitable for localized treatment of conditions related to estrogen levels.
Used in Drug Development:
Bifonazole is used as a research tool in the development of new drugs targeting C14orf1 and Cytochrome P450 2B4, as it has been identified as an inhibitor of these proteins. This makes it valuable for studying the mechanisms of action and potential therapeutic applications of these targets in various diseases and conditions.

Manufacturing Process

38.8g (0.15 mol) of 4-phenylbenzophenone are dissolved in 200 ml of ethanol and 39 (0.075 mol) of sodium borohydride are added. After heating for 15 hours under reflux, and allowing to cool, the reaction mixture is hydrolyzed with water containing a little hydrochloric acid. The solid thereby produced is purified by recrystallization from ethanol. 36 g (89% of theory) of (biphenyl- 4-yl)-phenyl-carbinol [alternatively named as diphenyl-phenyl carbinol or α- (biphenyl-4-yl)benzylalcohol] of melting point 72°-73°C are obtained. 13.6 g (0.2 mol) of imidazole are dissolved in 150 ml of acetonitrile and 3.5 ml of thionyl chloride are added at 10°C. 13 g (0.05 mol) of (biphenyl-4-yl)- phenyl-carbinol are added to the solution of thionyl-bis-imidazole thus obtained. After standing for 15 hours at room temperature, the solvent is removed by distillation in vacuo. The residue is taken up in chloroform and the solution is washed with water. The organic phase is collected, dried over sodium sulfate and filtered and the solvent is distilled off in vacuo. The oily residue is dissolved in ethyl acetate and freed from insoluble, resinous constituents by filtration. The solvent is again distilled off in vacuo and the residue is purified by recrystallization from acetonitrile, 8.7 g (56% of theory) of (biphenyl-4-yl)-imidazol-1-yl-phenylmethane [alternatively named as diphenyl-imidazolyl-(1)-phenyl-methane or as 1-(α-biphenyl-4- ylbenzyl)imidazole] of melting point 142°C are obtained.

Therapeutic Function

Antifungal

Check Digit Verification of cas no

The CAS Registry Mumber 60628-96-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,0,6,2 and 8 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 60628-96:
(7*6)+(6*0)+(5*6)+(4*2)+(3*8)+(2*9)+(1*6)=128
128 % 10 = 8
So 60628-96-8 is a valid CAS Registry Number.
InChI:InChI=1/C22H18N2/c1-3-7-18(8-4-1)19-11-13-21(14-12-19)22(24-16-15-23-17-24)20-9-5-2-6-10-20/h1-17,22H

60628-96-8 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (B4173)  Bifonazole  >98.0%(GC)(T)

  • 60628-96-8

  • 5g

  • 790.00CNY

  • Detail
  • TCI America

  • (B4173)  Bifonazole  >98.0%(GC)(T)

  • 60628-96-8

  • 25g

  • 2,450.00CNY

  • Detail
  • Sigma-Aldrich

  • (PHR1296)  Bifonazole  pharmaceutical secondary standard; traceable to PhEur

  • 60628-96-8

  • PHR1296-1G

  • 732.19CNY

  • Detail
  • Sigma-Aldrich

  • (B1110000)  Bifonazole  European Pharmacopoeia (EP) Reference Standard

  • 60628-96-8

  • B1110000

  • 1,880.19CNY

  • Detail
  • Sigma-Aldrich

  • (Y0001421)  Bifonazole for system suitability  European Pharmacopoeia (EP) Reference Standard

  • 60628-96-8

  • Y0001421

  • 1,880.19CNY

  • Detail
  • Sigma

  • (B3563)  Bifonazole  ≥98% (HPLC)

  • 60628-96-8

  • B3563-10MG

  • 430.56CNY

  • Detail
  • Sigma

  • (B3563)  Bifonazole  ≥98% (HPLC)

  • 60628-96-8

  • B3563-50MG

  • 1,711.71CNY

  • Detail

60628-96-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-[phenyl-(4-phenylphenyl)methyl]imidazole

1.2 Other means of identification

Product number -
Other names 1-(biphenyl-4-yl-phenyl-methyl)-1H-imidazole

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:60628-96-8 SDS

60628-96-8Synthetic route

(R,S)-1-<α-(4-Biphenylyl)benzyl>imidazole-4,5-dicarboxylic acid
162824-42-2

(R,S)-1-<α-(4-Biphenylyl)benzyl>imidazole-4,5-dicarboxylic acid

bifonazole
60628-96-8

bifonazole

Conditions
ConditionsYield
In diphenylether for 0.5h; Heating;98%
1H-imidazole
288-32-4

1H-imidazole

4-benzylbiphenyl
613-42-3

4-benzylbiphenyl

bifonazole
60628-96-8

bifonazole

Conditions
ConditionsYield
Stage #1: 4-benzylbiphenyl With N-Bromosuccinimide; 2,2'-azobis(isobutyronitrile) In tetrachloromethane for 0.833333h; Inert atmosphere; Reflux;
Stage #2: 1H-imidazole With potassium carbonate In acetonitrile for 1h; Reflux;
77%
Stage #1: 4-benzylbiphenyl With pyridine; tert.-butylhydroperoxide; iodine In decane; water at 80℃; for 12h; Schlenk technique; Inert atmosphere;
Stage #2: 1H-imidazole With formic acid; toluene-4-sulfonic acid In water at 180 - 200℃; for 10h; Schlenk technique; Inert atmosphere;
66%
1H-imidazole
288-32-4

1H-imidazole

C26H21N2O2S(1-)*Na(1+)

C26H21N2O2S(1-)*Na(1+)

bifonazole
60628-96-8

bifonazole

Conditions
ConditionsYield
With copper acetylacetonate; tetrabutylammomium bromide In toluene at 85℃; for 36h;52%
4-phenylbenzhydrol
7598-80-3

4-phenylbenzhydrol

1,1'-carbonyldiimidazole
530-62-1

1,1'-carbonyldiimidazole

bifonazole
60628-96-8

bifonazole

Conditions
ConditionsYield
In 1-methyl-pyrrolidin-2-one Heating;12%
phenylmagnesium bromide

phenylmagnesium bromide

1-[(4-methoxy-phenyl)-phenyl-methyl]-1H-imidazole

1-[(4-methoxy-phenyl)-phenyl-methyl]-1H-imidazole

bifonazole
60628-96-8

bifonazole

Conditions
ConditionsYield
With bis(dicyclohexylphenylphosphine)nickel(II) chloride In diethyl ether at 80℃; for 15h;
4-phenylbenzhydrol
7598-80-3

4-phenylbenzhydrol

bifonazole
60628-96-8

bifonazole

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 96 percent / DEAD, Ph3P / tetrahydrofuran / 24 h / Ambient temperature
2: 85 percent / NaOH / ethanol / 24 h / Heating
3: 98 percent / diphenyl ether / 0.5 h / Heating
View Scheme
Multi-step reaction with 2 steps
1.1: triethylamine / dichloromethane / 2 h / 0 - 20 °C / Inert atmosphere
2.1: sodium hydride / N,N-dimethyl-formamide; mineral oil / 2 h / 0 °C / Inert atmosphere
2.2: 0 - 100 °C / Inert atmosphere
View Scheme
1-<α-(4-Biphenylyl)benzyl>imidazole-4,5-dicarbonitrile
162824-36-4

1-<α-(4-Biphenylyl)benzyl>imidazole-4,5-dicarbonitrile

bifonazole
60628-96-8

bifonazole

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 85 percent / NaOH / ethanol / 24 h / Heating
2: 98 percent / diphenyl ether / 0.5 h / Heating
View Scheme
4-(chlorophenylmethyl)-1,1'-biphenyl
7515-73-3

4-(chlorophenylmethyl)-1,1'-biphenyl

1-(Trimethylsilyl)imidazole
18156-74-6

1-(Trimethylsilyl)imidazole

bifonazole
60628-96-8

bifonazole

Conditions
ConditionsYield
In acetonitrile
1H-imidazole
288-32-4

1H-imidazole

4-phenylbenzhydrol
7598-80-3

4-phenylbenzhydrol

bifonazole
60628-96-8

bifonazole

Conditions
ConditionsYield
Stage #1: 1H-imidazole; 4-phenylbenzhydrol With ammonium bromide In water at 125 - 130℃; for 2h; Industrial scale;
Stage #2: With ammonium bromide In water at 190 - 195℃; for 2h; Temperature; Industrial scale;
trimethylphenylsilane
768-32-1

trimethylphenylsilane

bifonazole
60628-96-8

bifonazole

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: silver(I) 4-methylbenzenesulfonate; dichloro(N-(diphenylphosphino)-N-isopropyl-1,1-diphenylphosphinamine) digold(I); [bis(acetoxy)iodo]benzene / 1,1,1-trichloroethane / 2 h / 110 °C / Inert atmosphere; Schlenk technique
2.1: aluminum oxide; sodium tetrahydroborate / ethanol / 0.67 h / 20 °C / Inert atmosphere
3.1: triethylamine / dichloromethane / 2 h / 0 - 20 °C / Inert atmosphere
4.1: sodium hydride / N,N-dimethyl-formamide; mineral oil / 2 h / 0 °C / Inert atmosphere
4.2: 0 - 100 °C / Inert atmosphere
View Scheme
(4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenyl)(phenyl)methanone
1063965-82-1

(4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenyl)(phenyl)methanone

bifonazole
60628-96-8

bifonazole

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: silver(I) 4-methylbenzenesulfonate; dichloro(N-(diphenylphosphino)-N-isopropyl-1,1-diphenylphosphinamine) digold(I); [bis(acetoxy)iodo]benzene / 1,1,1-trichloroethane / 2 h / 110 °C / Inert atmosphere; Schlenk technique
2.1: aluminum oxide; sodium tetrahydroborate / ethanol / 0.67 h / 20 °C / Inert atmosphere
3.1: triethylamine / dichloromethane / 2 h / 0 - 20 °C / Inert atmosphere
4.1: sodium hydride / N,N-dimethyl-formamide; mineral oil / 2 h / 0 °C / Inert atmosphere
4.2: 0 - 100 °C / Inert atmosphere
View Scheme
biphenyl-4-yl-phenyl-methanone
2128-93-0

biphenyl-4-yl-phenyl-methanone

bifonazole
60628-96-8

bifonazole

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: aluminum oxide; sodium tetrahydroborate / ethanol / 0.67 h / 20 °C / Inert atmosphere
2.1: triethylamine / dichloromethane / 2 h / 0 - 20 °C / Inert atmosphere
3.1: sodium hydride / N,N-dimethyl-formamide; mineral oil / 2 h / 0 °C / Inert atmosphere
3.2: 0 - 100 °C / Inert atmosphere
View Scheme
1H-imidazole
288-32-4

1H-imidazole

[1,1'-biphenyl]-4-yl(phenyl)methyl methanesulfonate

[1,1'-biphenyl]-4-yl(phenyl)methyl methanesulfonate

bifonazole
60628-96-8

bifonazole

Conditions
ConditionsYield
Stage #1: 1H-imidazole With sodium hydride In N,N-dimethyl-formamide; mineral oil at 0℃; for 2h; Inert atmosphere;
Stage #2: [1,1'-biphenyl]-4-yl(phenyl)methyl methanesulfonate In N,N-dimethyl-formamide; mineral oil at 0 - 100℃; Inert atmosphere;
61.9 mg
Diphenylmethane
101-81-5

Diphenylmethane

bifonazole
60628-96-8

bifonazole

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: dichloromethane / -40 - 20 °C / Schlenk technique; Inert atmosphere
2: bis(tri-t-butylphosphine)palladium(0); sodium hydrogencarbonate / dichloromethane; N,N-dimethyl-formamide / 12 h / 50 °C / Inert atmosphere; Schlenk technique
3: 2,2'-azobis(isobutyronitrile); N-Bromosuccinimide / tetrachloromethane / 0.83 h / Inert atmosphere; Reflux
4: potassium carbonate / acetonitrile / 1 h / Reflux
View Scheme
Multi-step reaction with 3 steps
1.1: dichloromethane / -40 - 20 °C / Inert atmosphere; Schlenk technique
2.1: sodium hydrogencarbonate; bis(tri-t-butylphosphine)palladium(0) / dichloromethane; N,N-dimethyl-formamide / 12 h / 50 °C / Inert atmosphere; Schlenk technique; Sealed tube
3.1: N-Bromosuccinimide; 2,2'-azobis(isobutyronitrile) / tetrachloromethane / 0.83 h / Inert atmosphere; Reflux
3.2: 1 h / Reflux
View Scheme
C25H19S2(1+)*CF3O3S(1-)

C25H19S2(1+)*CF3O3S(1-)

bifonazole
60628-96-8

bifonazole

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: bis(tri-t-butylphosphine)palladium(0); sodium hydrogencarbonate / dichloromethane; N,N-dimethyl-formamide / 12 h / 50 °C / Inert atmosphere; Schlenk technique
2: 2,2'-azobis(isobutyronitrile); N-Bromosuccinimide / tetrachloromethane / 0.83 h / Inert atmosphere; Reflux
3: potassium carbonate / acetonitrile / 1 h / Reflux
View Scheme
1H-imidazole
288-32-4

1H-imidazole

4-phenyl-benzhydryl bromide
60047-92-9

4-phenyl-benzhydryl bromide

bifonazole
60628-96-8

bifonazole

Conditions
ConditionsYield
With potassium carbonate In acetonitrile for 1h; Reflux;47.9 mg
4-benzylbiphenyl
613-42-3

4-benzylbiphenyl

bifonazole
60628-96-8

bifonazole

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 2,2'-azobis(isobutyronitrile); N-Bromosuccinimide / tetrachloromethane / 0.83 h / Inert atmosphere; Reflux
2: potassium carbonate / acetonitrile / 1 h / Reflux
View Scheme
2-phenyl-4,4,5,5-tetramethyl-1,3,2-dioxoborole
24388-23-6

2-phenyl-4,4,5,5-tetramethyl-1,3,2-dioxoborole

C25H19S2(1+)*CF3O3S(1-)

C25H19S2(1+)*CF3O3S(1-)

bifonazole
60628-96-8

bifonazole

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: sodium hydrogencarbonate; bis(tri-t-butylphosphine)palladium(0) / dichloromethane; N,N-dimethyl-formamide / 12 h / 50 °C / Inert atmosphere; Schlenk technique; Sealed tube
2.1: N-Bromosuccinimide; 2,2'-azobis(isobutyronitrile) / tetrachloromethane / 0.83 h / Inert atmosphere; Reflux
2.2: 1 h / Reflux
View Scheme
N-trifluoromethanesulfony-4-benzylaniline

N-trifluoromethanesulfony-4-benzylaniline

bifonazole
60628-96-8

bifonazole

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: tetrahydrofuran / 0.08 h / 20 °C / Schlenk technique; Inert atmosphere
1.2: 12.03 h / 70 °C / Schlenk technique; Inert atmosphere; Glovebox
2.1: iodine; pyridine; tert.-butylhydroperoxide / water; decane / 12 h / 80 °C / Schlenk technique; Inert atmosphere
2.2: 10 h / 180 - 200 °C / Schlenk technique; Inert atmosphere
View Scheme
p-benzylaniline
1135-12-2

p-benzylaniline

bifonazole
60628-96-8

bifonazole

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: triethylamine / dichloromethane / 12.5 h / -78 - 20 °C / Schlenk technique; Inert atmosphere
2.1: tetrahydrofuran / 0.08 h / 20 °C / Schlenk technique; Inert atmosphere
2.2: 12.03 h / 70 °C / Schlenk technique; Inert atmosphere; Glovebox
3.1: iodine; pyridine; tert.-butylhydroperoxide / water; decane / 12 h / 80 °C / Schlenk technique; Inert atmosphere
3.2: 10 h / 180 - 200 °C / Schlenk technique; Inert atmosphere
View Scheme
tetrafluoroboric acid diethyl ether
67969-82-8

tetrafluoroboric acid diethyl ether

sodium tetrafluoroborate
13755-29-8

sodium tetrafluoroborate

thianthrene-5-oxide
2362-50-7

thianthrene-5-oxide

bifonazole
60628-96-8

bifonazole

C34H25N2S2(1+)*BF4(1-)

C34H25N2S2(1+)*BF4(1-)

Conditions
ConditionsYield
Stage #1: tetrafluoroboric acid diethyl ether; thianthrene-5-oxide; bifonazole With trifluoroacetic anhydride In acetonitrile at 0 - 25℃; for 18h; Schlenk technique;
Stage #2: sodium tetrafluoroborate In dichloromethane; water
95%
Ethyl 4-bromobenzoate
5798-75-4

Ethyl 4-bromobenzoate

bifonazole
60628-96-8

bifonazole

ethyl 4-(1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-1H-imidazol-5-yl)benzoate

ethyl 4-(1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-1H-imidazol-5-yl)benzoate

Conditions
ConditionsYield
With potassium acetate; palladium diacetate at 150℃; for 16h; Inert atmosphere; Schlenk technique;90%
2,3,7,8-tetrafluorothianthrene-S-oxide

2,3,7,8-tetrafluorothianthrene-S-oxide

bifonazole
60628-96-8

bifonazole

C34H21F4N2S2(1+)

C34H21F4N2S2(1+)

Conditions
ConditionsYield
With trifluorormethanesulfonic acid; 2,3,7,8-tetrafluorothianthrene; trifluoroacetic anhydride In acetonitrile at 0 - 25℃; regioselective reaction;87%
trifluorormethanesulfonic acid
1493-13-6

trifluorormethanesulfonic acid

2,3,7,8-tetrafluorothianthrene-S-oxide

2,3,7,8-tetrafluorothianthrene-S-oxide

sodium triflate
2926-30-9

sodium triflate

bifonazole
60628-96-8

bifonazole

C34H21F4N2S2(1+)*CF3O3S(1-)

C34H21F4N2S2(1+)*CF3O3S(1-)

Conditions
ConditionsYield
Stage #1: trifluorormethanesulfonic acid; 2,3,7,8-tetrafluorothianthrene-S-oxide; bifonazole With trifluoroacetic anhydride In acetonitrile at 0 - 25℃; for 3h; Sealed tube;
Stage #2: sodium triflate In ethanol; dichloromethane; water
87%
4'-Bromopropiophenone
10342-83-3

4'-Bromopropiophenone

bifonazole
60628-96-8

bifonazole

1-(4-(1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-1H-imidazol-5-yl)phenyl)propan-1-one

1-(4-(1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-1H-imidazol-5-yl)phenyl)propan-1-one

Conditions
ConditionsYield
With potassium acetate; palladium diacetate at 150℃; for 16h; Inert atmosphere; Schlenk technique;77%
4-bromo-benzaldehyde
1122-91-4

4-bromo-benzaldehyde

bifonazole
60628-96-8

bifonazole

4-(1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-1H-imidazol-5-yl)benzaldehyde

4-(1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-1H-imidazol-5-yl)benzaldehyde

Conditions
ConditionsYield
With potassium acetate; palladium diacetate at 150℃; for 16h; Inert atmosphere; Schlenk technique;77%
3-bromo-1-trifluoromethylbenzene
401-78-5

3-bromo-1-trifluoromethylbenzene

bifonazole
60628-96-8

bifonazole

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-5-(3-(trifluoromethyl)phenyl)-1H-imidazole

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-5-(3-(trifluoromethyl)phenyl)-1H-imidazole

Conditions
ConditionsYield
With potassium acetate; palladium diacetate at 150℃; for 16h; Inert atmosphere; Schlenk technique;71%
p-trifluoromethylphenyl bromide
402-43-7

p-trifluoromethylphenyl bromide

bifonazole
60628-96-8

bifonazole

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-5-(4-(trifluoromethyl)phenyl)-1H-imidazole

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-5-(4-(trifluoromethyl)phenyl)-1H-imidazole

Conditions
ConditionsYield
With potassium acetate; palladium diacetate at 150℃; for 16h; Inert atmosphere; Schlenk technique;66%
Dibenzothiophene sulfoxide
1013-23-6

Dibenzothiophene sulfoxide

trifluorormethanesulfonic acid
1493-13-6

trifluorormethanesulfonic acid

bifonazole
60628-96-8

bifonazole

C34H25N2S(1+)*CF3O3S(1-)

C34H25N2S(1+)*CF3O3S(1-)

Conditions
ConditionsYield
With trifluoroacetic anhydride In acetonitrile at -40 - 25℃; for 2h; Schlenk technique; Glovebox; Inert atmosphere;65%
4-bromoisoquinoline
1532-97-4

4-bromoisoquinoline

bifonazole
60628-96-8

bifonazole

4-(1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-1H-imidazol-5-yl)isoquinoline

4-(1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-1H-imidazol-5-yl)isoquinoline

Conditions
ConditionsYield
With potassium acetate; palladium diacetate at 150℃; for 16h; Inert atmosphere; Schlenk technique;63%
4-bromobenzenecarbonitrile
623-00-7

4-bromobenzenecarbonitrile

bifonazole
60628-96-8

bifonazole

4-(1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-1H-imidazol-5-yl)-benzonitrile

4-(1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-1H-imidazol-5-yl)-benzonitrile

Conditions
ConditionsYield
With potassium acetate; palladium diacetate at 150℃; for 16h; Inert atmosphere; Schlenk technique;61%
3-cyanobromobenzene
6952-59-6

3-cyanobromobenzene

bifonazole
60628-96-8

bifonazole

3-(1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-1H-imidazol-5-yl)benzonitrile

3-(1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-1H-imidazol-5-yl)benzonitrile

Conditions
ConditionsYield
With potassium acetate; palladium diacetate at 150℃; for 16h; Inert atmosphere; Schlenk technique;61%
2-Acetyl-5-bromothiophene
5370-25-2

2-Acetyl-5-bromothiophene

bifonazole
60628-96-8

bifonazole

1-(5-(1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-1H-imidazol-5-yl)thiophen-2-yl)ethan-1-one

1-(5-(1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-1H-imidazol-5-yl)thiophen-2-yl)ethan-1-one

Conditions
ConditionsYield
With potassium acetate; palladium diacetate at 150℃; for 16h; Inert atmosphere; Schlenk technique;59%
o-cyanobromobenzene
2042-37-7

o-cyanobromobenzene

bifonazole
60628-96-8

bifonazole

2-(1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-1H-imidazol-5-yl)benzonitrile

2-(1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-1H-imidazol-5-yl)benzonitrile

Conditions
ConditionsYield
With potassium acetate; palladium diacetate at 150℃; for 16h; Inert atmosphere; Schlenk technique;58%
para-bromotoluene
106-38-7

para-bromotoluene

bifonazole
60628-96-8

bifonazole

A

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-2,5-di-p-tolyl-1H-imidazole

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-2,5-di-p-tolyl-1H-imidazole

B

C29H24N2

C29H24N2

Conditions
ConditionsYield
With cesium acetate; palladium diacetate at 150℃; for 48h; Inert atmosphere; Schlenk technique;A 58%
B n/a
1-bromo-4-methoxy-benzene
104-92-7

1-bromo-4-methoxy-benzene

bifonazole
60628-96-8

bifonazole

A

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-2,5-bis(4-methoxyphenyl)-1H-imidazole

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-2,5-bis(4-methoxyphenyl)-1H-imidazole

B

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-5-(4-methoxyphenyl)-1H-imidazole

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-5-(4-methoxyphenyl)-1H-imidazole

Conditions
ConditionsYield
With cesium acetate; palladium diacetate at 150℃; for 48h; Inert atmosphere; Schlenk technique;A 57%
B n/a
bromobenzene
108-86-1

bromobenzene

bifonazole
60628-96-8

bifonazole

A

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-2,5-diphenyl-1H-imidazole

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-2,5-diphenyl-1H-imidazole

B

C28H22N2

C28H22N2

Conditions
ConditionsYield
With cesium acetate; palladium diacetate at 150℃; for 48h; Inert atmosphere; Schlenk technique;A 55%
B n/a
[(Co(C20H8N4(C6H5)3(C6H4CONH2)))2]

[(Co(C20H8N4(C6H5)3(C6H4CONH2)))2]

bifonazole
60628-96-8

bifonazole

Co(O(C4NH2C(C6H5))3H(OH)C4NH2C6H4C2NO)(bifonazole)

Co(O(C4NH2C(C6H5))3H(OH)C4NH2C6H4C2NO)(bifonazole)

Conditions
ConditionsYield
With air In chloroform treatment of Co-complex with rac-bifonazole; XRD, UV-Vis;46%
o-trifluoromethylphenyl bromide
392-83-6

o-trifluoromethylphenyl bromide

bifonazole
60628-96-8

bifonazole

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-5-(2-(trifluoromethyl)phenyl)-1H-imidazole

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-5-(2-(trifluoromethyl)phenyl)-1H-imidazole

Conditions
ConditionsYield
With potassium acetate; palladium diacetate at 150℃; for 16h; Inert atmosphere; Schlenk technique;45%
3-Chloropyridine
626-60-8

3-Chloropyridine

bifonazole
60628-96-8

bifonazole

3-(1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-1H-imidazol-5-yl)pyridine

3-(1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-1H-imidazol-5-yl)pyridine

Conditions
ConditionsYield
With potassium acetate; palladium diacetate at 150℃; for 16h; Inert atmosphere; Schlenk technique;45%
bifonazole
60628-96-8

bifonazole

para-nitrophenyl bromide
586-78-7

para-nitrophenyl bromide

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-5-(4-nitrophenyl)-1H-imidazole

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-5-(4-nitrophenyl)-1H-imidazole

Conditions
ConditionsYield
With potassium acetate; palladium diacetate at 150℃; for 16h; Inert atmosphere; Schlenk technique;43%
1-Bromonaphthalene
90-11-9

1-Bromonaphthalene

bifonazole
60628-96-8

bifonazole

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-5-(naphthalen-1-yl)-1H-imidazole

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-5-(naphthalen-1-yl)-1H-imidazole

Conditions
ConditionsYield
With potassium acetate; palladium diacetate at 150℃; for 16h; Inert atmosphere; Schlenk technique;42%
5-bromopyrimidine
4595-59-9

5-bromopyrimidine

bifonazole
60628-96-8

bifonazole

5-(1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-1H-imidazol-5-yl)pyrimidine

5-(1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-1H-imidazol-5-yl)pyrimidine

Conditions
ConditionsYield
With potassium acetate; palladium diacetate at 150℃; for 16h; Inert atmosphere; Schlenk technique;41%
2-bromonaphthalene
580-13-2

2-bromonaphthalene

bifonazole
60628-96-8

bifonazole

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-5-(naphthalen-2-yl)-1H-imidazole

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-5-(naphthalen-2-yl)-1H-imidazole

Conditions
ConditionsYield
With potassium acetate; palladium diacetate at 150℃; for 16h; Inert atmosphere; Schlenk technique;39%
1-bromo-4-tert-butylbenzene
3972-65-4

1-bromo-4-tert-butylbenzene

bifonazole
60628-96-8

bifonazole

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-5-(4-(tert-butyl)-phenyl)-1H-imidazole

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-5-(4-(tert-butyl)-phenyl)-1H-imidazole

Conditions
ConditionsYield
With potassium acetate; palladium diacetate at 150℃; for 16h; Inert atmosphere; Schlenk technique;34%
1,2-(methylenedioxy)-4-bromobenzene
2635-13-4

1,2-(methylenedioxy)-4-bromobenzene

bifonazole
60628-96-8

bifonazole

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-5-(benzo[d][1,3]-dioxol-5-yl)-1H-imidazole

1-([1,1′-biphenyl]-4-yl(phenyl)methyl)-5-(benzo[d][1,3]-dioxol-5-yl)-1H-imidazole

Conditions
ConditionsYield
With potassium acetate; palladium diacetate at 150℃; for 16h; Inert atmosphere; Schlenk technique;28%

60628-96-8Relevant academic research and scientific papers

Controlling Multiple Active Sites on Pd?CeO2 for Sequential C?C Cross-coupling and Alcohol Oxidation in One Reaction System

Antink, Wytse Hooch,Bok, Jinsol,Cho, Sung-Pyo,Choi, Hyunwoo,Hyeon, Taeghwan,Jung, Yoon,Kim, Do Heui,Kim, Jiheon,Kim, Jongchan,Kim, Ju Hee,Kim, Sumin,Kim, Young Gyu,Ko, Wonjae,Kwak, Minjoon,Lee, Byoung-Hoon,Lee, Chan Woo,Lee, Eunwon,Lee, Kug-Seung,Lee, Seong Chan,Yim, Guk Hee,Yoo, Dongwon

, (2022/01/22)

Ceria (CeO2)-supported metal catalysts have been widely utilized for various single-step chemical transformations. However, using such catalysts for a multistep organic reaction in one reaction system has rarely been achieved. Here, we investigate multiple active sites on Pd?CeO2 catalysts and optimize them for a multistep reaction of C?C cross-coupling and alcohol oxidation. Atomic-level imaging and spectroscopic studies reveal that metallic Pd0 and Pd?CeO2 interface are active sites on Pd?CeO2 for C?C cross-coupling and oxidation, respectively. These active sites are controlled under the structural evolution of Pd?CeO2 during reductive heat-treatments. Accordingly, we found that optimally reduced Pd?CeO2 catalysts containing ~1.5 nm-sized Pd nanoclusters with both sites in balance are ideal for multistep chemical transformations in one reaction system. Our strategy to design supported metal catalysts leads to one-pot sequential synthetic protocols for pharmaceutical building blocks.

NHC-Nickel Catalyzed C-N Bond Cleavage of Mono-protected Anilines for C-C Cross-Coupling

Xia, Ji-Bao,Zhang, Zheng-Bing

, p. 9609 - 9613 (2020/12/21)

A Ni-catalyzed aryl C-N bond cleavage of mono-protected anilines, N-arylsulfonamides, has been developed. A new N-heterocyclic carbene derived from benzoimidazole shows high reactivity for the C-N cleavage/C-C cross-coupling reaction. The ortho-directing group is not required to break the C-N bond of sulfonyl-protected anilines, which are not limited to π-extended anilines. The mechanistic studies have revealed that a sulfamidomagnesium salt is the key coupling intermediate.

Preparation method of para-substituted aryl compound

-

, (2020/06/09)

The invention discloses a preparation method of a para-substituted aryl compound shown as a formula (I) which is described in the specfication. The preparation method is characterized by comprising the following step of: subjecting an aryl sulfonium salt shown as a formula (II) which is described in the specfication and boride to a coupling reaction in a solvent in an inert atmosphere under the action of alkali and a palladium catalyst to obtain the para-substituted aryl compound. According to the method, mono-substituted aromatic hydrocarbon is taken as a substrate, the aryl sulfonium salt isconstructed in situ, and the palladium catalyst catalyzes the aryl sulfonium salt constructed in situ to undergo the Suzuki-Miyaura coupling reaction, so a mono-substituted aromatic hydrocarbon para-arylation or alkenylation product is constructed quickly and efficiently. The method is mild in conditions, high in substrate universality and wide in tolerance of a heterocyclic coupling substrate.

para-Selective arylation and alkenylation of monosubstituted arenes using thianthreneS-oxide as a transient mediator

Chen, Xiao-Yue,Nie, Xiao-Xue,Wu, Yichen,Wang, Peng

, p. 5058 - 5061 (2020/05/18)

Using thianthreneS-oxide (TTSO) as a transient mediator,para-arylation and alkenylation of mono-substituted arenes have been demonstratedviaapara-selective thianthrenation/Pd-catalyzed thio-Suzuki-Miyaura coupling sequence under mild conditions. This reaction features a broad substrate scope, and functional group and heterocycle tolerance. The versatility of this approach was further demonstrated by late-stage functionalization of complex bioactive scaffolds, and direct synthesis of some pharmaceuticals, including Tetriprofen, Ibuprofen, Bifonazole, and LJ570.

One-pot process for preparing bifonazole

-

Paragraph 0006; 0018-0023, (2018/01/13)

The invention relates to the technical field of medicine synthesis and in particular relates to a one-pot process for preparing bifonazole. According to the process disclosed by the invention, 4-phenyl benzhydrol is prepared by reducing 4-phenyl benzophenone by potassium borohydride, and a catalyst is added without treatment; and the 4-phenyl benzhydrol is reacted with imidazole in the presence of the catalyst so as to prepare the bifonazole. According to the method disclosed by the invention, the bifonazole with the yield of 76-82% can be obtained. The process disclosed by the invention is simple, less in steps, convenient to operate, does not need any special equipment, is suitable for large-scale industrial production, high in product yield and low in cost, and is obviously improved relative to other processes.

Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17)-Part II: Core rigidification and influence of substituents at the methylene bridge

Hu, Qingzhong,Negri, Matthias,Jahn-Hoffmann, Kerstin,Zhuang, Yan,Olgen, Sureyya,Bartels, Marc,Mueller-Vieira, Ursula,Lauterbach, Thomas,Hartmann, Rolf W.

, p. 7715 - 7727 (2008/12/23)

Thirty-five novel substituted imidazolyl methylene biphenyls have been synthesized as CYP17 inhibitors for the potential treatment of prostate cancer. Their activities have been tested with recombinant human CYP17 expressed in Escherichia coli. Promising compounds were tested for selectivity against CYP11B1, CYP11B2, and hepatic CYP enzymes 3A4, 1A2, 2B6 and 2D6. The core rigidified compounds (30-35) were the most active ones, being much more potent than Ketoconazole and reaching the activity of Abiraterone. However, they were not very selective. Another rather potent and more selective inhibitor (compound 23, IC50 = 345 nM) was further examined in rats regarding plasma testosterone levels and pharmacokinetic properties. Compared to the reference Abiraterone, 23 was more active in vivo, showed a longer plasma half-life (10 h) and a higher bioavailability. Using our CYP17 homology protein model, docking studies with selected compounds were performed to study possible interactions between inhibitors and amino acid residues of the active site.

Copper carbenoid mediated N-alkylation of imidazoles and its use in a novel synthesis of bifonazole

Cuevas-Ya?ez, Erick,Serrano, Juan Manuel,Huerta, Gloria,Muchowski, Joseph M.,Cruz-Almanza, Raymundo

, p. 9391 - 9396 (2007/10/03)

1H-Imidazoles are readily N-alkylated by a Cu(acac)2 mediated reaction with α-diazocarbonyl compounds or with diazoalkanes generated in situ from the corresponding p-toluensulfonyl hydrazones. The antifungal agent bifonazole was prepared by the latter method. Graphical Abstract.

Nickel-catalyzed cross-coupling of aryl grignard reagents with aromatic alkyl ethers: An efficient synthesis of unsymmetrical biaryls

Dankwardt, John W.

, p. 2428 - 2432 (2007/10/03)

New substrates for biaryl synthesis: aromatic ethers undergo nickel-catalyzed cross-coupling with aryl Grignard reagents to give unsymmetrical biaryls in excellent yields (see scheme). Both the nature of the nickel catalyst and the choice of solvent are crucial for reaching high levels of conversion.

Chiral azole derivatives. 2. Synthesis of enantiomerically pure 1-alkylimidazoles

Corelli,Summa,Brogi,Monteagudo,Botta

, p. 2008 - 2015 (2007/10/02)

4,5-Dicyanoimidazole has been reacted with racemic and enantiopure alcohols 7 (entries 1-7) under Mitsunobu conditions to give 1-alkyl-4,5-dicyanoimidazole derivatives 8, which in turn have been transformed by hydrolysis and decarboxylation into 1-alkylimidazoles 10 in good overall yield and high enantiomeric excess. In contrast, when applied to benzyl and benzhydryl alcohols (entries 8-15), this sequence afforded the final compounds in good overall yield, but as racemic mixtures. The 1-(1-phenylalkyl)imidazole derivative (S)-(+)-24 was, however, prepared in enantiopure form starting from the corresponding (S)-(-)-α-methylbenzylamine (21) using the Marckwald procedure, which entailed the alkylation of 21 with bromoacetaldehyde dimethyl acetal, followed by the construction of the imidazole ring through reaction with potassium thiocyanate and final Ra-Ni desulfuration. Following the same procedure, (S)-(+)-10c was also synthesized, proving the stereochemical outcome of the Mitsunobu reaction.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 60628-96-8